GlassScriptPhysician profile
Jared Wayne Schiefer
NPI 1548881196
$15,178.89
in general payments reported to CMS, 2019-2025
56 companies · $924 in 2025
The $924 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,581 · 2022: $3,595 · 2023: $4,292 · 2024: $3,788 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,003.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,163.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,982.00 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,708.13 | 2021-2025 | Xarelto, Spravato |
| Lilly USA, LLC | $1,194.75 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $748.49 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $666.27 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.42 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $423.70 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $399.56 | 2022-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $344.41 | 2021-2025 | Otezla, Repatha, Otezla |
| Alkermes, INC. | $339.70 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Bayer Healthcare Pharmaceuticals INC. | $304.00 | 2021-2024 | |
| Axsome Therapeutics, INC. | $301.15 | 2023-2024 | Auvelity |
| Lundbeck LLC | $286.62 | 2022-2024 | Rexulti, Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.34 | 2022-2025 | Xifaxan |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $241.14 | 2021-2024 | Trintellix |
| Antares Pharma, INC. | $240.35 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Glaxosmithkline, LLC. | $233.99 | 2022-2024 | Trelegy Ellipta, Arexvy, Bexsero |
| Tris Pharma INC | $227.34 | 2023-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $218.81 | 2021-2023 | Adzenys Xr-Odt |
| Sumitomo Pharma America, INC. | $217.47 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $211.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $191.88 | 2021-2023 | Livalo, Seglentis |
| Exact Sciences Corporation | $189.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $154.28 | 2022 | |
| Astellas Pharma US INC | $142.24 | 2023-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $138.98 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $117.61 | 2021-2024 | Nuzyra |
| Acerus Pharmaceuticals Corporation | $91.25 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $81.72 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $69.10 | 2023-2024 | Verquvo, Gardasil 9, Gardasil |
| Neurocrine Biosciences, INC. | $68.52 | 2023-2025 | Ingrezza, Ongentys |
| Azurity Pharmaceuticals, INC. | $63.04 | 2024-2025 | Edarbi, Horizant, Azmiro |
| Amarin Pharma, INC. | $62.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.26 | 2022-2023 | Eliquis |
| Dexcom, INC. | $56.42 | 2022-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $45.57 | 2023 | Quviviq |
| Almatica Pharma LLC | $43.09 | 2022-2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Nestle Healthcare Nutrition INC. | $42.33 | 2022 | |
| Halozyme INC | $38.54 | 2023 | |
| Vanda Pharmaceuticals INC. | $35.29 | 2025 | Fanapt |
| Insulet Corporation | $32.04 | 2025 | Omnipod |
| Edwards Lifesciences Corporation | $29.22 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Impel Pharmaceuticals INC. | $23.31 | 2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $23.09 | 2023 | Austedo |
| Ironshore Pharmaceuticals INC. | $21.99 | 2023 | Jornay Pm |
| Clarus Therapeutics INC. | $20.40 | 2021 | |
| Corcept Therapeutics | $19.75 | 2022 | |
| Shield Therapeutics INC | $19.44 | 2022 | |
| Aytu Biopharma, INC. | $17.67 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.75 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $13.62 | 2022 | |
| Valinor Pharma, LLC | $13.58 | 2024 | Movantik |
| Vistapharm, INC. | $13.22 | 2021 | |
| Electromed, INC. | $13.19 | 2023 | Smartvest |
| Arbor Pharmaceuticals, INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Schiefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.